Your browser doesn't support javascript.
loading
Cissampelos pareira Linn: Natural Source of Potent Antiviral Activity against All Four Dengue Virus Serotypes.
Sood, Ruchi; Raut, Rajendra; Tyagi, Poornima; Pareek, Pawan Kumar; Barman, Tarani Kanta; Singhal, Smita; Shirumalla, Raj Kumar; Kanoje, Vijay; Subbarayan, Ramesh; Rajerethinam, Ravisankar; Sharma, Navin; Kanaujia, Anil; Shukla, Gyanesh; Gupta, Y K; Katiyar, Chandra K; Bhatnagar, Pradip K; Upadhyay, Dilip J; Swaminathan, Sathyamangalam; Khanna, Navin.
Afiliación
  • Sood R; Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Raut R; Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Tyagi P; Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Pareek PK; Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Barman TK; Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Singhal S; Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Shirumalla RK; Department of Pharmacology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Kanoje V; Department of Pharmacology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Subbarayan R; Department of Pharmacology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Rajerethinam R; Department of Pharmacology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Sharma N; Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Kanaujia A; Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Shukla G; Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Gupta YK; Department of Pharmacology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
  • Katiyar CK; Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Bhatnagar PK; Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Upadhyay DJ; Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India.
  • Swaminathan S; Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
  • Khanna N; Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
PLoS Negl Trop Dis ; 9(12): e0004255, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26709822
ABSTRACT

BACKGROUND:

Dengue, a mosquito-borne viral disease, poses a significant global public health risk. In tropical countries such as India where periodic dengue outbreaks can be correlated to the high prevalence of the mosquito vector, circulation of all four dengue viruses (DENVs) and the high population density, a drug for dengue is being increasingly recognized as an unmet public health need. METHODOLOGY/PRINCIPAL

FINDINGS:

Using the knowledge of traditional Indian medicine, Ayurveda, we developed a systematic bioassay-guided screening approach to explore the indigenous herbal bio-resource to identify plants with pan-DENV inhibitory activity. Our results show that the alcoholic extract of Cissampelos pariera Linn (Cipa extract) was a potent inhibitor of all four DENVs in cell-based assays, assessed in terms of viral NS1 antigen secretion using ELISA, as well as viral replication, based on plaque assays. Virus yield reduction assays showed that Cipa extract could decrease viral titers by an order of magnitude. The extract conferred statistically significant protection against DENV infection using the AG129 mouse model. A preliminary evaluation of the clinical relevance of Cipa extract showed that it had no adverse effects on platelet counts and RBC viability. In addition to inherent antipyretic activity in Wistar rats, it possessed the ability to down-regulate the production of TNF-α, a cytokine implicated in severe dengue disease. Importantly, it showed no evidence of toxicity in Wistar rats, when administered at doses as high as 2g/Kg body weight for up to 1 week. CONCLUSIONS/

SIGNIFICANCE:

Our findings above, taken in the context of the human safety of Cipa, based on its use in Indian traditional medicine, warrant further work to explore Cipa as a source for the development of an inexpensive herbal formulation for dengue therapy. This may be of practical relevance to a dengue-endemic resource-poor country such as India.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Extractos Vegetales / Cissampelos / Dengue / Virus del Dengue Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: PLoS Negl Trop Dis Asunto de la revista: MEDICINA TROPICAL Año: 2015 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Extractos Vegetales / Cissampelos / Dengue / Virus del Dengue Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: PLoS Negl Trop Dis Asunto de la revista: MEDICINA TROPICAL Año: 2015 Tipo del documento: Article País de afiliación: India